LTI to Acquire Powerupcloud Technologies
Larsen & Toubro Infotech Ltd. (NSE: LTI) (BSE: 540005), a global technology consulting and digital solutions company is acquiring Powerupcloud Technologies Pvt. Ltd., a fast-growing cloud consulting company headquartered in Bengaluru, and helping clients across India, Singapore, UAE and USA. With more than 180 employees, Powerup brings a strong team of cloud consulting, artificial intelligence and data analytics professionals to LTI.
Founded in 2015, Powerup is a born-in-the-cloud, Premier Consulting Partner of AWS. It is the only AWS certified partner in APAC to have both Data & Analytics Competency and Machine Learning Competency, and one of the few certified partners of AWS with competencies across Migration, DevOps, Financial Services, Well-Architected, and Security & Compliance. With expertise across cloud, big data, artificial intelligence, and product engineering, Powerup is also a Gold Partner of Microsoft Azure and a Cloud Consulting Partner of Google Cloud Platform.
Powerup has executed over 150 projects in cloud transformation. Powerup would add two AI-based platforms to LTI’s powerful suite of offerings. CloudEnsure.io, an autonomous Cloud Governance Platform that continuously monitors an enterprise’s cloud services, detects security and compliance violations in real-time and recommends or executes appropriate fixes. The other platform is Botzer.io, an Enterprise AI Platform that helps organizations adopt AI faster across Natural Language Processing, Image Recognition, Deep Learning use-cases and saves time spent in trial-and-error experimentation.
Sanjay Jalona, Chief Executive Officer & Managing Director, LTI, said: “We see a huge market opportunity for cloud consulting across all sectors and regions. Our clients are adopting cloud to digitize their core operations and becoming data-driven organizations. Powerup strengthens our ability to partner with them in their cloud transformation journey. I welcome the customers, employees and partners of Powerup to the fast-growing LTI family.”
Siva S, Founder & CEO, Powerup, said: “With its global customer base and agility, LTI makes the perfect home for next phase of growth of Powerup. Our expertise across major public cloud platforms offers us an enormous opportunity to grow, learn, iterate and build well-engineered technology solutions for enterprises. We are excited about the potential of rapid growth and expansion with LTI.”
Powerup is the sixth acquisition by LTI since the company got listed in 2016 and fourth in this calendar year. Earlier in 2019, LTI acquired Ruletronics, a boutique Pega Consulting company, N+P (NEILSEN+PARTNER), a Temenos Wealthsuite specialist, and Lymbyc, an advanced analytics company.
About LTI:
LTI (NSE: LTI) is a global technology consulting and digital solutions Company helping more than 360 clients succeed in a converging world. With operations in 30 countries, we go the extra mile for our clients and accelerate their digital transformation with LTI’s Mosaic platform enabling their mobile, social, analytics, IoT and cloud journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivaled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 30,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees and shareholders. Find more at http://www.Lntinfotech.com or follow us at @LTI_Global
About Powerupcloud Technologies Pvt. Ltd.:
Powerup is a “born-in-the-cloud” company focused on helping businesses move to the cloud. The dynamic team at Powerup strives for customer satisfaction and delivers unmatched cloud consulting services to businesses with undivided attention and support. Our consulting team helps implement, migrate and optimize cloud applications for global corporations. We also help build Big Data analytics platforms to enable enterprises extract more value from their environment. A Premier Consulting Partner with AWS, a Gold Partner with Microsoft Azure and a Cloud Consulting Partner of Google Cloud Platform, Powerup’s certified team is here to help customers achieve more on the cloud.
More information at https://www.powerupcloud.com
More Information:
LTI to Acquire Advanced Analytics Firm Lymbyc
LTI to Acquire Germany Based NIELSEN+PARTNER
LTI Acquires Ruletronics, a Boutique Pega® Consulting Company
Connect with LTI:
- Read our News and Blogs
- Follow us on Twitter, Facebook and LinkedIn
- Meet us at Temenos Community Forum, 2019
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005696/en/
Contact information
Media Contacts:
Shambahvi Revandkar
PR & Media Relations - India
+91-97695-09545
Shambavi.revandkar@lntinfotech.com
Karin Bakis
PR & Media Relations - USA
+1-978-998-1578
karin.bakis@lntinfotech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom